PMC7497900_01
(A) Computed tomography (CT) abdomen and pelvis (pre-treatment) showing hepatomegaly and several hypodense lesions throughout the liver parenchyma consistent with liver metastases. (B) CT abdomen and pelvis (post-treatment) showing enlargement of existing lesions and new hepatic metastases.
JKCVHL-7-007-g001.jpg
PMC7497900_01_JKCVHL-7-007-g001.jpg
F1
A computed tomography (CT) scan of her abdomen and pelvis disclosed hepatomegaly and several hypodense lesions throughout the liver parenchyma consistent with liver metastases (Figure 1A). Unfortunately, after completing 12 weeks on combination axitinib/pembrolizumab, repeat CT scans for assessment of response disclosed progression of liver metastases (Figure 1B).